An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the ...

As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...

Jared Holz, Mizuho Healthcare Sector strategist, joins 'Closing Bell Overtime' to talk Moderna and Novo Nordisk.

Equity markets performed well in January, as they often do, but as the dust settles on that early-year run, the strategy for long-term investors remains the same: Invest in companies that can perform ...

Moderna, Inc. (NASDAQ:MRNA) today announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine in the European Union (EU), Norway and North Macedonia. Under the resulting ...

In 2023, Moderna initiated a study on a “pandemic ... with Dr. Sanjay Gupta every Friday from the CNN Health team. The US does have vaccines against H5 viruses in its Strategic National ...

At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from a September forecast of $2.5 billion to $3.5 billion. And Moderna said it ...

The study included vaccine candidates against H5 and ... With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna ...

Moderna works on mRNA vaccines, which use synthetic code to instruct ... The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to ...

While some of the initial zeal around localized vaccine production in Africa has waned since the height of the COVID-19 pandemic, efforts to bolster the continent’s immunization autonomy—especially | ...